{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"APTN","limit":50},"count":44,"signals":[{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":19,"context":", more effective or otherwise clinically superior to the orphan designated product. The inability to obtain or failure to maintain adequate product exclusivity for our product candidates could have a material adverse effect on our business prospects, results of operations and financial condition. *Other Healthcare Laws and Compliance Requirements* Our sales, promotion, medical education, clinical research, and other act","filed_date":"2026-04-01","accession":"0001213900-26-038568","full_text":"https://origin.rootz.global/static/filing/0001213900-26-038568.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":12,"context":"re not separately compensated for their service as directors. *Executive Officer Compensation* ** This section discusses the material components of the executive compensation program for the Companys named executive officers (NEOs) who appear in the Summary Compensation Table below. In 2025, the named executive officers and their positions with the Company were as follows: |  |  |  Michael J. Roberts: President and Chie","filed_date":"2026-04-01","accession":"0001213900-26-038568","full_text":"https://origin.rootz.global/static/filing/0001213900-26-038568.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":29,"context":"h the contractual lock-up restrictions) to sell the shares of registered Common Stock. The resale, or anticipated or potential resale, of a substantial number of shares of our Common Stock may have a material negative impact on the market price of our Common Stock and could make it more difficult for our shareholders to sell their shares of Common Stock at such times and at such prices as they deem desirable. **Dividend","filed_date":"2025-07-28","accession":"0001213900-25-068130","full_text":"https://origin.rootz.global/static/filing/0001213900-25-068130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":16,"context":"not separately compensated for their service as directors. **Executive Officer Compensation** ** This section discusses the material components of the executive compensation program for the Companys named executive officers who appear in the Summary Compensation Table below. In 2024, the named executive officers and their positions with the Company were as follows: |  | Michael J. Robert: President and Chief Executive","filed_date":"2025-07-28","accession":"0001213900-25-068130","full_text":"https://origin.rootz.global/static/filing/0001213900-25-068130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":29,"context":"h the contractual lock-up restrictions) to sell the shares of registered Common Stock. The resale, or anticipated or potential resale, of a substantial number of shares of our Common Stock may have a material negative impact on the market price of our Common Stock and could make it more difficult for our shareholders to sell their shares of Common Stock at such times and at such prices as they deem desirable. **Dividend","filed_date":"2025-05-16","accession":"0001213900-25-044585","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":16,"context":"not separately compensated for their service as directors. **Executive Officer Compensation** ** This section discusses the material components of the executive compensation program for the Companys named executive officers who appear in the Summary Compensation Table below. In 2024, the named executive officers and their positions with the Company were as follows: |  | Michael J. Robert: President and Chief Executive","filed_date":"2025-05-16","accession":"0001213900-25-044585","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":16,"context":", more effective or otherwise clinically superior to the orphan designated product. The inability to obtain or failure to maintain adequate product exclusivity for our product candidates could have a material adverse effect on our business prospects, results of operations and financial condition. **Other Healthcare Laws and Compliance Requirements** Our sales, promotion, medical education, clinical research, and other a","filed_date":"2025-04-15","accession":"0001213900-25-031878","full_text":"https://origin.rootz.global/static/filing/0001213900-25-031878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"not separately compensated for their service as directors. **Executive Officer Compensation** ** This section discusses the material components of the executive compensation program for the Companys named executive officers who appear in the Summary Compensation Table below. In 2024, the named executive officers and their positions with the Company were as follows: |  | Michael J. Robert: President and Chief Executive","filed_date":"2025-04-15","accession":"0001213900-25-031878","full_text":"https://origin.rootz.global/static/filing/0001213900-25-031878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"**TABLE OF CONTENTS** **** |  |  |  Page | | |  PART I | | |  | | |  Item 1. |  Business |  1 | | |  Item 1A. |  Risk Factors |  6 | | |  Item 1B. |  Unresolved Staff Comments |  6 | | |  Item 1C. |  Cybersecurity |  6 | | |  Item 2. |  Properties |  6 | | |  Item 3. |  Legal Proceedings |  6 | | |  Item 4. |  Mine Safety Disclosures |  6 | | |  |  | | |  PART II | | |  | | |  Item 5. |  Market for Reg","filed_date":"2024-04-01","accession":"0001213900-24-028681","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028681.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. | | |  | Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. | | |  | We currently rely significantly on third parties to conduct our nonclinical testing and clini","filed_date":"2025-07-28","accession":"0001213900-25-068130","full_text":"https://origin.rootz.global/static/filing/0001213900-25-068130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. | | |  | Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. | | |  | We currently rely significantly on third parties to conduct our nonclinical testing and clini","filed_date":"2025-05-16","accession":"0001213900-25-044585","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":72,"match_count":9,"context":"executive officer of the Company since inception.See Director Compensation below. |  | The following compensation discussion addresses all compensation awarded to, earned by, or paid to the Companys named executive officers. The Companys officer and director has not received any cash or other compensation since inception through the date of this filing. No compensation of any nature has been paid for on account of serv","filed_date":"2024-04-01","accession":"0001213900-24-028681","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028681.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on its business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the Companys business, results of op","filed_date":"2025-11-14","accession":"0001213900-25-110559","full_text":"https://origin.rootz.global/static/filing/0001213900-25-110559.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on its business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the Companys business, results of op","filed_date":"2025-08-14","accession":"0001213900-25-076361","full_text":"https://origin.rootz.global/static/filing/0001213900-25-076361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the business, results of operations","filed_date":"2025-05-15","accession":"0001213900-25-044083","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044083.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the business, results of operations","filed_date":"2026-08-13","accession":"0001213900-26-089081","full_text":"https://origin.rootz.global/static/filing/0001213900-26-089081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"o locate suitable acquisition candidates. No revenue has been generated by the Company since inception. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. The Companys plan of operation for the remainder of the fiscal year shall be to continue its efforts to locate suitable acquisition candidate","filed_date":"2024-11-14","accession":"0001213900-24-098361","full_text":"https://origin.rootz.global/static/filing/0001213900-24-098361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"o locate suitable acquisition candidates. No revenue has been generated by the Company since inception. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. The Companys plan of operation for the remainder of the fiscal year shall be to continue its efforts to locate suitable acquisition candidate","filed_date":"2024-08-14","accession":"0001213900-24-068816","full_text":"https://origin.rootz.global/static/filing/0001213900-24-068816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"o locate suitable acquisition candidates. No revenue has been generated by the Company since inception. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. The Companys plan of operation is to continue its efforts to locate suitable acquisition candidates. Our principal business objective for the","filed_date":"2024-05-15","accession":"0001213900-24-043492","full_text":"https://origin.rootz.global/static/filing/0001213900-24-043492.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"o locate suitable acquisition candidates. No revenue has been generated by the Company since inception. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. The Companys plan of operation for the remainder of the fiscal year shall be to continue its efforts to locate suitable acquisition candidate","filed_date":"2023-11-14","accession":"0001213900-23-086982","full_text":"https://origin.rootz.global/static/filing/0001213900-23-086982.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the business, results of operations","filed_date":"2025-04-15","accession":"0001213900-25-031875","full_text":"https://origin.rootz.global/static/filing/0001213900-25-031875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the business, operating results and financial condition and its ability to achieve its intended business objectives. Any of these actions could materially harm the business, results of operations","filed_date":"2025-02-18","accession":"0001213900-25-014630","full_text":"https://origin.rootz.global/static/filing/0001213900-25-014630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"0754cd3f563c88063d7a2d969bcc619197890c90524 **Words:** 1,263 --- EX-99.1 2 ea030312801ex99-1.htm PRESS RELEASE, DATED AUGUST 20, 2026 **Exhibit 99.1** ** ** **Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101** **APTN-101s unique mechanism of action is designed to overcome the limitations for effective treatment of","filed_date":"2026-08-25","accession":"0001213900-26-093520","full_text":"https://origin.rootz.global/static/filing/0001213900-26-093520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"h an exercise price of $4.40 per share and an aggregate grant date fair value of $2,231,900 which will be recognized ratably over the requisite service periods. The options vest in equal monthly installments on the last day of each calendar month over 48 months.  F-17 The Company granted a consultant (the Consultant) options to purchase an aggregate of 219,693 shares of the Companys common stock, wit","filed_date":"2026-04-01","accession":"0001213900-26-038568","full_text":"https://origin.rootz.global/static/filing/0001213900-26-038568.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":24,"match_count":3,"context":"ments and footnote disclosures. **** **4. REVERSE RECAPITALIZATION** **** **The Merger** **** On February 11, 2025, Unite, through its wholly owned subsidiary Adaptin Acquisition Co., consummated the Merger with Private Adaptin. Pursuant to the Merger, Private Adaptin was the surviving corporation and became a wholly owned subsidiary of Unite, and all of the outstanding common stock of Private Adaptin was co","filed_date":"2025-05-15","accession":"0001213900-25-044083","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044083.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"h an exercise price of $4.40 per share and an aggregate grant date fair value of $2,231,900 which will be recognized ratably over the requisite service periods. The options vest in equal monthly installments on the last day of each calendar month over 48 months. Expenses related to these awards are included within research and development expense and general and administrative expense on the condense","filed_date":"2025-11-14","accession":"0001213900-25-110559","full_text":"https://origin.rootz.global/static/filing/0001213900-25-110559.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"arket value of a share of the Companys Common Stock on the date of grant, as determined by the board of directors. The Anti-Dilution Options, if any, will become exercisable in four equal annual installments, in each case subject to the continued employment of each Executive with the Company on the date each such vesting milestone is achieved, and will be subject to the terms of the Companys equity i","filed_date":"2025-04-15","accession":"0001213900-25-031878","full_text":"https://origin.rootz.global/static/filing/0001213900-25-031878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"execution of the Duke License as a research and development expense as they were deemed to be part of the acquisition price of the IPR&D. Reimbursement for these costs will be made in four equal installments with the first two payments having been made in 2023 and an additional payment in 2024. At December 31, 2024, the Company had a remaining liability of $81,782 included in accounts payable on the","filed_date":"2025-04-15","accession":"0001213900-25-031875","full_text":"https://origin.rootz.global/static/filing/0001213900-25-031875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":8,"match_count":1,"context":"ements and related disclosures. **** **4. REVERSE RECAPITALIZATION** **** **The Merger** **** On February 11, 2025, Unite, through its wholly owned subsidiary Adaptin Acquisition Co., consummated the Merger with Private Adaptin. Pursuant to the Merger, Private Adaptin was the surviving corporation and became a wholly owned subsidiary of Unite, and all of the outstanding common stock of Private Adaptin was co","filed_date":"2025-11-14","accession":"0001213900-25-110559","full_text":"https://origin.rootz.global/static/filing/0001213900-25-110559.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"arket value of a share of the Companys Common Stock on the date of grant, as determined by the board of directors. The Anti-Dilution Options, if any, will become exercisable in four equal annual installments, in each case subject to Dr. Hewitts continued employment with the Company on the date each such vesting milestone is achieved, and will be subject to the terms of the Companys equity incentive p","filed_date":"2025-10-06","accession":"0001213900-25-096532","full_text":"https://origin.rootz.global/static/filing/0001213900-25-096532.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":8,"match_count":1,"context":"itional Financing Period, on a fully diluted basis and assuming the exercise of all outstanding options (whether or not then exercisable), is equal to his ownership immediately following the Companys merger with Unite Acquisition 1 Corp. on February 11, 2025, as determined on a fully diluted basis and assuming the exercise of all outstanding options (whether or not then exercisable). The per share exercise p","filed_date":"2025-10-06","accession":"0001213900-25-096532","full_text":"https://origin.rootz.global/static/filing/0001213900-25-096532.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"arket value of a share of the Companys common stock on the date of grant, as determined by the board of directors. The Anti-Dilution Options, if any, will become exercisable in four equal annual installments, in each case subject to the continued employment of each Executive with the Company on the date each such vesting milestone is achieved, and will be subject to the terms of the Companys equity i","filed_date":"2025-08-14","accession":"0001213900-25-076361","full_text":"https://origin.rootz.global/static/filing/0001213900-25-076361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":8,"match_count":1,"context":"ements and related disclosures. **** **4. REVERSE RECAPITALIZATION** **** **The Merger** **** On February 11, 2025, Unite, through its wholly owned subsidiary Adaptin Acquisition Co., consummated the Merger with Private Adaptin. Pursuant to the Merger, Private Adaptin was the surviving corporation and became a wholly owned subsidiary of Unite, and all of the outstanding common stock of Private Adaptin was co","filed_date":"2025-08-14","accession":"0001213900-25-076361","full_text":"https://origin.rootz.global/static/filing/0001213900-25-076361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":8,"match_count":1,"context":"nificant resources and may never be successful. If approved, the failure of our product candidates resulting from the BRiTE platform or any of our other products to significantly penetrate current or new markets would negatively impact our business, financial condition and results of operations. **To be commercially successful, physicians must be persuaded that using our products for treatment of cancer, in","filed_date":"2025-07-28","accession":"0001213900-25-068130","full_text":"https://origin.rootz.global/static/filing/0001213900-25-068130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"bstantial additional funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in the global healthcare environment. In addition, if our product candidates are commercialized, we may need to accelera","filed_date":"2025-07-28","accession":"0001213900-25-068130","full_text":"https://origin.rootz.global/static/filing/0001213900-25-068130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":8,"match_count":1,"context":"nificant resources and may never be successful. If approved, the failure of our product candidates resulting from the BRiTE platform or any of our other products to significantly penetrate current or new markets would negatively impact our business, financial condition and results of operations. **To be commercially successful, physicians must be persuaded that using our products for treatment of cancer, in","filed_date":"2025-05-16","accession":"0001213900-25-044585","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"bstantial additional funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in the global healthcare environment. In addition, if our product candidates are commercialized, we may need to accelera","filed_date":"2025-05-16","accession":"0001213900-25-044585","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044585.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"arket value of a share of the Companys common stock on the date of grant, as determined by the board of directors. The Anti-Dilution Options, if any, will become exercisable in four equal annual installments, in each case subject to the continued employment of each Executive with the Company on the date each such vesting milestone is achieved, and will be subject to the terms of the Companys equity i","filed_date":"2025-05-15","accession":"0001213900-25-044083","full_text":"https://origin.rootz.global/static/filing/0001213900-25-044083.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"r ability to control costs associated with our operations; intellectual property risks; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties to supply drug substance and drug product for our clinical","filed_date":"2025-04-09","accession":"0001213900-25-030320","full_text":"https://origin.rootz.global/static/filing/0001213900-25-030320.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":8,"match_count":1,"context":"or the Company), a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, announced today the successful completion of a reverse merger of a wholly owned subsidiary of Unite Acquisition 1 Corp. with and into Adaptin, with Adaptin continuing as the surviving entity. Adaptin Bio expects to trade on the OTC Markets. In connection with the","filed_date":"2025-04-09","accession":"0001213900-25-030320","full_text":"https://origin.rootz.global/static/filing/0001213900-25-030320.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"pment expense as they were deemed to be part of the acquisition price of the IPR&D. Any unpaid amounts are reflected in accrued expenses. Reimbursement for these costs will be made in four equal installments with the first two payments having been made in 2023 and an additional payment made in 2024. At September 30, 2024, the Company had a remaining liability of $81,783 included in accounts payable o","filed_date":"2025-02-18","accession":"0001213900-25-014630","full_text":"https://origin.rootz.global/static/filing/0001213900-25-014630.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"ember 8, 2025, which removed both performance-based vesting conditions and replaced them with a single service-based condition. Under the amended terms, 109,846 options now vest in equal monthly installments over 48 months beginning on the last day of April 2026, subject to the Consultants continued service. The modification date was April 6, 2026 and the incremental compensation cost resulting from","filed_date":"2026-08-13","accession":"0001213900-26-089081","full_text":"https://origin.rootz.global/static/filing/0001213900-26-089081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":8,"match_count":1,"context":"on date over the vesting period of the modified award. 4. REVERSE RECAPITALIZATION The Merger On February 11, 2025, Unite, through its wholly owned subsidiary Adaptin Acquisition Co., consummated the Merger with Private Adaptin. Pursuant to the Merger, Private Adaptin was the surviving corporation and became a wholly owned subsidiary of Unite, and all of the outstanding common stock of Private Adaptin was co","filed_date":"2026-08-13","accession":"0001213900-26-089081","full_text":"https://origin.rootz.global/static/filing/0001213900-26-089081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APTN","company":"ADAPTIN BIO, INC.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"backlog_growth","strength":8,"match_count":1,"context":"000 new cases annually. The glioblastoma multiforme treatment market is valued at $3.02 billion in 2025, and researchers forecast an 8% CAGR over the next five years, reaching $4.44 billion by 2030.1 Growing demand for therapies that prolong survival is a top driver of the projected growth. **** |  | 1 | Source: https://www.mordorintelligence.com/industry-reports/glioblastoma-multiforme-treatment-market |  | **","filed_date":"2026-08-25","accession":"0001213900-26-093520","full_text":"https://origin.rootz.global/static/filing/0001213900-26-093520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"2e5af05f69248edccafc0c00505a5bd2f13907bbde69a8c01daadca3764c3e7f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"1adc592141035c2041e714c5166878d87008b9daa3fa8964acadd37f11cf1e0b","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":40,"hourly_limit":500,"remaining":460,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}